Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eledon Pharmaceuticals (ELDN) Interest & Investment Income (2016 - 2017)

Eledon Pharmaceuticals filings provide 4 years of Interest & Investment Income readings, the most recent being $26000.0 for Q1 2017.

  • On a quarterly basis, Interest & Investment Income fell 51.85% to $26000.0 in Q1 2017 year-over-year; TTM through Mar 2017 was $136000.0, a 27.66% decrease, with the full-year FY2016 number at $164000.0, down 5.75% from a year prior.
  • Interest & Investment Income hit $26000.0 in Q1 2017 for Eledon Pharmaceuticals, up from $23000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $55000.0 in Q4 2015 to a low of $23000.0 in Q4 2016.
  • Median Interest & Investment Income over the past 4 years was $40000.0 (2015), compared with a mean of $40769.2.
  • The widest YoY moves for Interest & Investment Income: up 96.0% in 2016, down 58.18% in 2016.
  • Eledon Pharmaceuticals' Interest & Investment Income stood at $53000.0 in 2014, then grew by 3.77% to $55000.0 in 2015, then crashed by 58.18% to $23000.0 in 2016, then rose by 13.04% to $26000.0 in 2017.
  • The last three reported values for Interest & Investment Income were $26000.0 (Q1 2017), $23000.0 (Q4 2016), and $38000.0 (Q3 2016) per Business Quant data.